NAC Supplement Shows Promise for Protecting Brain Health in Parkinson's Disease

Cornell University researchers conducted a groundbreaking study to test whether N-acetylcysteine (NAC) supplementation could restore protective antioxidant levels in the brains of people with Parkinson's disease. The trial used advanced magnetic resonance spectroscopy to directly measure brain glutathione levels in living patients for the first time.

The randomized, placebo-controlled study enrolled 50 participants who received either 1800mg NAC, 3600mg NAC, or placebo daily for 30 days. Researchers used non-invasive brain imaging to measure glutathione concentrations before and after treatment, along with comprehensive motor function assessments and oxidative stress markers.

Previous post-mortem studies had shown that Parkinson's patients have significantly depleted brain glutathione, the body's master antioxidant that protects neurons from damage. This study aimed to determine whether oral NAC supplementation could cross the blood-brain barrier and restore these critical protective levels in living patients.

The trial also investigated whether any increases in brain glutathione would be dose-dependent and correlate with improvements in clinical symptoms or oxidative stress profiles. Researchers conducted detailed motor function tests to assess potential connections between antioxidant restoration and symptom improvement.

This completed study represents the first objective documentation of whether dietary NAC supplementation can address glutathione deficits in living Parkinson's patients' brains. The findings could provide crucial evidence for larger neuroprotective trials and offer new hope for slowing disease progression through targeted antioxidant therapy.